Skip to main content
. 2019 Aug 29;20(17):4233. doi: 10.3390/ijms20174233

Figure 1.

Figure 1

Examples of expression of cell surface target antigens on CD34+ stem cells in normal bone marrow (NBM) and patients with acute myeloid leukemia (AML). Target expression on aspirated CD34+/CD38 cells (left panels, red histograms) and CD34+/CD38+ BM cells (right panels, blue histograms) was determined by fluorochrome-conjugated antibodies (as depicted) and multi-color flow cytometry. Normal/reactive BM (NBM) was obtained from lymphoma patients without BM involvement or was purchased, and leukemic BM was obtained from three patients with AML. All patients gave written informed consent before BM aspiration was performed. The study was approved by the ethics committee of the Medical University of Vienna. Reactivity of the test antibodies (CD34+/CD38 stem cells: red histograms; CD34+/CD38+ stem/progenitor cells: blue histograms) was assessed on a FACSCantoII (BD Biosciences). Antibody reactivity was controlled by isotype-matched control antibodies (open black histograms). Flow cytometry data were analyzed using FlowJo 8.8.7 software (Flowjo).